Unknown

Dataset Information

0

Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?

ABSTRACT:

SUBMITTER: Le L 

PROVIDER: S-EPMC6987360 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?

Le Laura L   van Dams Ritchell R   Lee Percy P  

Translational lung cancer research 20191201 Suppl 4

Similar Datasets

Unknown Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer.
| S-EPMC8342563 | biostudies-literature
Unknown First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
| S-EPMC8645705 | biostudies-literature
Unknown First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
| S-EPMC7734005 | biostudies-literature
Unknown LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.
| S-EPMC11572187 | biostudies-literature
Unknown Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
| S-EPMC10394135 | biostudies-literature
Unknown KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer.
| S-EPMC10483082 | biostudies-literature
Unknown Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
| S-EPMC9989798 | biostudies-literature
Unknown Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
| S-EPMC5099520 | biostudies-literature
Unknown First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis.
| S-EPMC11774708 | biostudies-literature
Unknown JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
| S-EPMC9293160 | biostudies-literature